| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 01/23/2008 | EP1880734A2 Multi-component vaccine to protect against disease caused by haemophilus influenzae and moraxella catarrhalis |
| 01/23/2008 | EP1880733A1 Method for increasing longevity of a human being and animals |
| 01/23/2008 | EP1880214A1 Method for identifying modulators of noah10 useful for treating alzheimer's disease |
| 01/23/2008 | EP1880012A1 Vaccine composition |
| 01/23/2008 | EP1879998A2 Leptospirosis culture process |
| 01/23/2008 | EP1879923A2 Cathepsin s antibody |
| 01/23/2008 | EP1879922A2 Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells |
| 01/23/2008 | EP1879921A2 Host cell specific binding molecules capable of neutralizing viruses and uses thereof |
| 01/23/2008 | EP1879919A2 Polypeptide, vaccine and use thereof |
| 01/23/2008 | EP1879914A2 Ehrlichia canis diva (differentiate infected from vaccinated animals) |
| 01/23/2008 | EP1879908A1 Immunoglobulin fraction and process therefor |
| 01/23/2008 | EP1879617A1 Antibody or a fragment thereof, having neutralizing activity against hiv but not against il2 |
| 01/23/2008 | EP1879616A2 Superantibody synthesis and use in detection, prevention and treatment of disease |
| 01/23/2008 | EP1879615A2 Methods for the rapid expansion of antigen specific t-cells |
| 01/23/2008 | EP1879614A2 Vaccine |
| 01/23/2008 | EP1879613A2 Peptide conjugate compositions and methods for the prevention and treatment of alzheimer's disease |
| 01/23/2008 | EP1879612A2 Use of native peptides and their optimized derivatives for vaccination |
| 01/23/2008 | EP1879601A1 Disease therapy using dying or dead cells |
| 01/23/2008 | EP1879598A1 Adjuvant comprising oligonucleotide and non toxic lps |
| 01/23/2008 | EP1879588A2 Combination therapy |
| 01/23/2008 | EP1879587A2 Methods and compositions for treating or preventing cancer |
| 01/23/2008 | EP1879448A2 Compositions and methods related to serpin spi6 |
| 01/23/2008 | EP1620554B1 Recombinant fel d 1 allergen |
| 01/23/2008 | EP1436316B1 Subcellular targeting of therapeutic proteins |
| 01/23/2008 | EP1272514B1 Dna encoding human vanilloid receptor vr3 |
| 01/23/2008 | EP1240332B1 Streptococcus pyogenes virulence genes and proteins and their use |
| 01/23/2008 | EP1240310B1 Method of inactivating microorganisms |
| 01/23/2008 | EP1220925B1 Chlamydia antigens and corresponding dna fragments and uses thereof |
| 01/23/2008 | EP1210372B1 Human monoclonal antibodies to her2/neu |
| 01/23/2008 | EP1141315B1 Modified hiv env polypeptides |
| 01/23/2008 | EP1140998B1 Chlamydia antigens and corresponding dna fragments and uses thereof |
| 01/23/2008 | EP1135498B1 Antibody variants with higher binding affinity compared to parent antibodies |
| 01/23/2008 | EP1080201B1 Novel post-transcriptional regulatory elements and uses thereof |
| 01/23/2008 | CN101111521A Humanized antibody specific for tumor necrosis factor-alpha |
| 01/23/2008 | CN101111514A Compositions comprising pathogen-associated molecular patterns and antigens and their use to stimulate an immune response |
| 01/23/2008 | CN101111265A Synergistic combination of xolair/omalizumab/e25 with immunosuppressive agent |
| 01/23/2008 | CN101111264A Stabilized liquid polypeptide formulations |
| 01/23/2008 | CN101111263A Delaying or preventing onset of multiple sclerosis |
| 01/23/2008 | CN101111262A Pharmaceutical composition useful for vaccines |
| 01/23/2008 | CN101111261A 糖偶联物疫苗 Saccharide conjugate vaccines |
| 01/23/2008 | CN101111260A Survivin peptide vaccine |
| 01/23/2008 | CN101111259A Antilymphocyte antibody induction by combination of an s1p receptor agonist/modulator and of immunosuppressive drugs |
| 01/23/2008 | CN101111258A Emulsified composition for dilution and cancer vaccine composition |
| 01/23/2008 | CN101111227A Method for production of bioresorbable microparticles microparticles thus obtained and use thereof |
| 01/23/2008 | CN101111154A Combination of immuno gene therapy and chemotherapy for treatment of cancer and hyperproliferative diseases |
| 01/23/2008 | CN101108882A Fusion protein of HIV regulatory/accessory proteins |
| 01/23/2008 | CN101108877A Nucleic acids and proteins from streptococcus pneumoniae |
| 01/23/2008 | CN101108250A Mono- and disaccharide derivatives |
| 01/23/2008 | CN101108249A Triple killed vaccine for fowl and method of preparing the same |
| 01/23/2008 | CN101108248A Method of preparing newcastle disease, infectiousness bronchitis bigeminy killed vaccine |
| 01/23/2008 | CN101108247A Vibrio anguillarum exuviae vaccine and method of preparing the same |
| 01/23/2008 | CN100363057C Use of melanoma differentiation associated gene (mda-7) for reversing cancerous phenotype |
| 01/23/2008 | CN100363054C Cancer therapy using whole glucan particles and antibodies |
| 01/22/2008 | US7321026 Framework-patched immunoglobulins |
| 01/22/2008 | US7321023 SP16 protein |
| 01/22/2008 | US7320873 for diagnosing autoimmune disease (rheumatoid arthritis) activity using monoclonal antibodies |
| 01/22/2008 | US7320861 Polyvalent vaccine against diseases caused by papilloma viruses, method for the production and the use thereof |
| 01/22/2008 | US7320857 Characterization of the earliest stages of the severe acute respiratory syndrome (SARS) virus and uses thereof |
| 01/22/2008 | US7320796 Nucleic acid bonding to tumor necrosis factor; genetic engineering; culture product |
| 01/22/2008 | US7320795 Rodent hepatitis B virus core proteins as vaccine platforms and methods of use thereof |
| 01/22/2008 | US7320794 Membrane permeability of a substrate, hydantoin-transporter activity |
| 01/22/2008 | US7320793 Comprises ordered and repetitive antigen or antigenic determinant array for developing vaccines for treatment of infectious diseases, allergies and cancer; microarrays |
| 01/22/2008 | US7320792 Preventives or remedies for psoriasis containing as the active ingredient IL-6 antagonist |
| 01/22/2008 | US7320791 Monoclonal antibody for analysis and clearance of polyethylene glycol and polyethylene glycol-modified molecules |
| 01/22/2008 | US7320790 Humanized antibodies |
| 01/22/2008 | US7320789 Antibody inhibitors of GDF-8 and uses thereof |
| 01/22/2008 | US7320786 Administering lyposomes of photosensitive receptors or ligands targeted to specific tissues, exposure to light causing destruction of bound tissues; treatment of eye neovascular disease due to macular degeneration, diabetes |
| 01/22/2008 | CA2382535C Mixed micellar pharmaceutical delivery system and method of preparation |
| 01/22/2008 | CA2380569C Chimeric polypeptides, method for production and uses thereof |
| 01/22/2008 | CA2276491C Early detection of mycobacterial disease |
| 01/22/2008 | CA2215520C Chlamydia vaccines |
| 01/17/2008 | WO2008008881A1 Virosomes, methods of preparation, and immunogenic compositions |
| 01/17/2008 | WO2008008879A2 Nanoparticulate formulations of modafinil |
| 01/17/2008 | WO2008008526A2 Treating obesity and gastro-intestinal disorders using botulinum toxin |
| 01/17/2008 | WO2008008455A2 Method of treating multiple myeloma |
| 01/17/2008 | WO2008008052A2 Improved ultrasonic inspection using acoustic modeling |
| 01/17/2008 | WO2008007804A1 ANTIHUMAN α9 INTEGRIN ANTIBODY AND USE OF THE SAME |
| 01/17/2008 | WO2008007755A1 Cell death inducer |
| 01/17/2008 | WO2008007711A1 Sart3-derived peptide useful in cancer vaccine therapy for hla-a3 supertype allele-positive prostate cancer patient |
| 01/17/2008 | WO2008007146A1 Process for preparing particles of proteinaceous material |
| 01/17/2008 | WO2008007021A1 Method of immunisation against the four serotypes of dengue |
| 01/17/2008 | WO2008006927A1 Peptide and nucleotide sequences of anisakis spp., antibodies that recognise said sequences and uses of same |
| 01/17/2008 | WO2008006895A2 Methods and compositions for increasing the efficiency of therapeutic antibodies using gamma delta t cell activators |
| 01/17/2008 | WO2008006554A2 Glyco-engineered antibodies |
| 01/17/2008 | WO2008006235A2 Scfv antibodies which pass epithelial and/or endothelial layers |
| 01/17/2008 | WO2007131017A3 A METHOD FOR DELIVERING A HUMAN CHORIONIC GONADOTROPIN (hCG) VACCINE FOR LONG-ACTING ANTIBODY PRODUCTION |
| 01/17/2008 | WO2007117577A3 High affinity human antibodies to human il-18 receptor |
| 01/17/2008 | WO2007109161A3 Detection of hiv-infected cell subsets |
| 01/17/2008 | WO2007106073A3 Modified pathogens for use as vaccines |
| 01/17/2008 | WO2007096192A3 Production of biologically active proteins |
| 01/17/2008 | WO2007081974A3 Viral hepatitis treatment |
| 01/17/2008 | WO2007079448A3 Three component carbohydrate vaccine |
| 01/17/2008 | WO2007078879A3 Lipopeptide compositions and methods of use thereof |
| 01/17/2008 | WO2007050099A3 Recombinant bcg strains with attenuated immunosuppresive properties |
| 01/17/2008 | WO2007019247A3 Virus-like particles as vaccines for paramyxovirus |
| 01/17/2008 | WO2007016239A3 Herpes simplex virus mutant and uses therefore |
| 01/17/2008 | WO2006104389A9 Methods and means for diagnostics, prevention and treatment of mycobacterium infections and tuberculosis disease |
| 01/17/2008 | WO2006062779A3 Anti-integrin immunoconjugates, methods and uses |
| 01/17/2008 | WO2006026394A3 Method of eliciting an immune response against hiv |
| 01/17/2008 | WO2005046571A3 Lactoferrin as an adjuvant in cancer vaccines |